AD			
	(Leave	blank)	

Award Number: W81XWH-09-2-0065

TITLE: Trial of Naltrexone and Dextromethorphan for Gulf War Veterans' Illness

PRINCIPAL INVESTIGATOR: William Joel Meggs, MD, PhD

CONTRACTING ORGANIZATION: East Carolina University Greenville, NC 27858

REPORT DATE: July 2010

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and mainta data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 24302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a valid OMB control purper. PLASS DO NOT PETURN TO THE ABOVE ADDRESS.

valid OMB control number. PLEASE DO NOT RETURN	YOUR FORM TO THE ABOVE ADDRESS.	
1. REPORT DATE (DD-MM-YYYY)	2. REPORT TYPE	3. DATES COVERED (From - To)
31-JUL-2010	Annual	1 JUL 2009 - 30 JUN 2010
4. TITLE AND SUBTITLE		5a. CONTRACT NUMBER
Trial of Naltrexone and D	extromethorphan for Gulf War	
Veterans' Illness		5b. GRANT NUMBER
		W81XWH-09-2-0065
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S)		5d. PROJECT NUMBER
William J. Meggs, MD, PhD		
		5e. TASK NUMBER
meggsw@ecu.edu		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME	E(S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REI
East Carolina University		
Greenville, NC 2758-4353		
9. SPONSORING / MONITORING AGENCY US Army Medical Research	` ,	10. SPONSOR/MONITOR'S ACRONYM
_		
Ft. Detrick, MD 21702-501	Ζ	11. SPONSOR/MONITOR'S REPORT
		NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STA		
Approved for public relea	se, distribution unlimited	
13. SUPPLEMENTARY NOTES		
14. ABSTRACT		
1 = -7	zed, controlled trial of dextrome	thorphan & naltrexone for gulf
illness.		

15. SUBJECT TERMS

Dextromethorphan, naltexone, gulf war illness

16. SECURITY CLAS unclassified	SSIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PI USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE	טט	8	19b. TELEPHONE NUMBER (inclu code)

Table of Contents

	<u>Page</u>
Introduction	4
Body	5
Key Research Accomplishments	6
Reportable Outcomes	7
Conclusion	8
References	n/a
Appendices	n/a

INTRODUCTION:

The purpose of the research is to study the efficacy of naltrexone and dextromethorphan for Gulf War Illness. The hypothesis to be tested is that Gulf War Illness results from low grade central nervous system inflammation. Naltrexone and Dextromethorphan were chosen for investigation due to the work of Dr. John Hong and others, that these medications modulate central nervous system inflammation.

BODY:

We are still working on the first task, which is to obtain Institutional Review
Board approval for the study. We have successfully obtained approval by the East
Caroline University Institutional Review Board. The Department of Defense Institutional
Review Board has undertaken several protracted reviews.

KEY RESEARCH ACCOMPLISHMENTS:

There are no key research accomplishments because we cannot begin the research until we obtain DOD IRB approval to start the research.

REPORTABLE OUTCOMES:

None at this time.

CONCLUSION:

It is very difficult to get IRB approval for this project, requiring multiple levels of review, each of which takes months, and each of which requires extensive clarifications, revisions, and further IRB review.